GSK and the University of Oxford will invest up to £50 ($62) million to advance the understanding of how cancer develops, which could inform the future development of vaccines. The agreement establishes the GSK-Oxford Cancer Immuno-Prevention Programme, which unites expertise from four departments across the University and builds on Oxford’s… Read More
A new study has shown that non-cancerous cells positioned close to tumours can affect how cancer responds to treatment. The researchers say factoring in the effects of these cells could improve drug development and provide new insights into the most effective use of existing cancer medications. … Read More
For World Cancer Day, Diana Spencer collates five most significant oncology research advances so far in 2025. An AI drug discovery breakthrough Results of an in vivo mouse colorectal cancer model study have shown a 60% life extension for Oxford Drug Design’s first-in-class approach against multiple… Read More
Allogene Therapeutics has been given the green light from the US Food and Drug Administration (FDA) for a rheumatology basket study of ALLO-329, an investigational allogeneic CAR-T product. The Phase I RESOLUTION basket trial will evaluate the safety and preliminary efficacy of ALLO-329 in patients with systemic lupus erythematosus, including… Read More
Vyome Therapeutics has shared interim results from its Phase II proof of concept study of VT-1953 topical gel in people with malignant fungating wounds (MFW). VT-1953, which exerts an immuno-anti-inflammatory effect by targeting TLR-MD2 and DNA gyrase, met its primary endpoint in this interim analysis, with patients… Read More
A study co-led by University of Toronto (U of T) researchers and Insilico Medicine has demonstrated the potential of quantum computing and artificial intelligence (AI) to transform the drug discovery pipeline. “It’s an exciting time to be working at the interface of chemistry, quantum computing and AI. Read More
A therapeutic vaccine targeting human papillomavirus type 16 (HPV16) induced regression in high-grade precancerous cervical lesions, according to a study published in Clinical Cancer Research, a journal of the American Association for Cancer Research (AACR). Dr Refika Yigit, principal investigator and Oncological Gynaecologist at University… Read More
Cancer Research UK, Cytovation and the Norwegian Cancer Society have signed an agreement to bring Cytovation’s lead asset, CY-101, into a multi-national Phase II clinical trial for patients with adrenocortical carcinoma (ACC). CY-101, developed by Cytovation, is a synthetic peptide with a dual function. It selectively targets and destroys cancer… Read More
Phesi has released the results of its annual global analysis of all clinical trials conducted in 2024, using data from its AI-driven Trial Accelerator platform (Figure 1). The analysis of 67,469 recruiting clinical trials reveals that breast cancer is the world’s most studied disease for the fourth consecutive year… Read More
The amount of a protein called CD74 can indicate which people with bowel cancer may respond best to immunotherapy, new research has revealed. If integrated into the clinic, the researchers at the Francis Crick Institute and Barts Cancer Institute, Queen Mary University of London, say testing for… Read More
Results of an in vivo mouse colorectal cancer model study have shown a 60% life extension for Oxford Drug Design’s first-in-class approach against multiple tumours. The results follow previous in vivo validation of the therapeutic candidates and have led to… Read More
The combination of Scancell’s Modi-1 and a checkpoint blockade has shown promise in HPV negative head and neck squamous cell carcinoma (SCCHN) in an ongoing Phase IIa study. The Phase IIa dose expansion ModiFY study is evaluating the safety, tolerability, and preliminary efficacy of Modi-1 in combination… Read More
Avacta has announced positive early efficacy data for its peptide drug conjugate, AVA6000, demonstrating clinically meaningful tumour shrinkage in patients with salivary gland cancer (SGC). AVA6000 consists of doxorubicin chemotherapy conjugated with Avacta’s pre|CISION peptide, specifically cleaved by fibroblast activation protein-alpha (FAP) in the tumour microenvironment. Read More
Rappta Therapeutics, a company developing anti-cancer drugs, has entered a global license agreement with SpringWorks Therapeutics for RPT04402, a first-in-class molecular glue of specific protein phosphatase 2A (PP2A) complexes. Rappta’s PP2A-reactivating technologies are developed using high resolution structural data and have the potential to create a new class of anti-cancer… Read More
GSK has revealed it will acquire IDRx, a Boston-based, clinical-stage biopharmaceutical company developing precision therapeutics for the treatment of gastrointestinal stromal tumours (GIST). Under the agreement, GSK will pay $1 billion upfront, with potential for an additional $150 million success-based regulatory approval milestone payment. The acquisition includes lead molecule, IDRX-42,… Read More
EsoBiotec and Pregene Biopharma have dosed the first patient in an investigator-initiated clinical trial in China of ESO-T01 for relapsed/refractory multiple myeloma. ESO-T01 is an immune shielded lentiviral vector that reprograms T lymphocytes in vivo into highly effective BCMA CAR-T cells. The clinical… Read More
